This may sound like hair-splitting, but identifying patients who are most at risk is not exactly the same thing as identifying patients who will benefit the most from a specific treatment. Here is a link to an article posted a few weeks ago by Jean, under the heading "New test for early stagers" :
http://www.medicalnewstoday.com/articles/81755.php It discusses research being done at MD Anderson using three different genomic tests to determine risk and sensitivity to chemo and endocrine therapies in the same patient, all independently of each other. The results yielded a number of patients classified as high risk that were insensitive to both therapies. It will no more help a high risk patient than a low risk patient to treat them with a therapy that will not work for the specific person. We need better tools to pair the patient with the treatment.
Hopeful
Threaded Mode